|
Regulation, Specification, or Guidance
|
Requirement
|
21 CFR Part 312.62 (b) 21 CFR Part 812.140 (a-3)
|
16.1 The system shall be able to create and accurately maintain complete case histories, allowing them to be electronically signed.
|
21 CFR Part 312.57 (a)
21 CFR Part 312.62 (a)
21 CFR Part 606.165
21 CFR Part 812.140 (a-2) and (b-2)
|
16.2 The system shall be able to accurately track the reception, use, storage, shipment and disposition of investigational cannabis-related drugs, including details such as, but not limited to, type, quantity, unique identifiers, dates, names, reasoning for return or disposition, shipping demographics, and signatures.
|
21 CFR Part 58.81 (a)
21 CFR Part 211.100
21 CFR Part 211.111
21 CFR Part 211.192
21 CFR Part 211.194
21 CFR Part 606.171
42 CFR Part 493.1253 (b-2)
ABFT Accreditation Manual C-16
ABFT Accreditation Manual F-2
ABFT Accreditation Manual J-3
ASTM E1578-18 E-9-1
EPA ERLN Laboratory Requirements 3.3
EPA QA/G-5 2.2.4
ISO/IEC 17025:2017 7.2.1.7
ISO/IEC 17025:2017 7.2.2.1
ISO/IEC 17025:2017 7.10.2
ISO/IEC 17025:2017 8.7.1
OECD GLP Principles 7.3
USDA Administrative Procedures for the PDP 8.2.2
WHO Technical Report Series, #986, Annex 2, 16.3
|
16.3 The system shall be able to record instances of identified nonconformance and method deviation, as well as the actions required to restore the process to conformity. In the case of a planned deviation, the system shall require documentation, justification, proof of validation, adjusted reference intervals, and authorization for the deviated process.
|
42 CFR Part 493.1282 ASTM E1578-18 E-9-2
|
16.4 The system should clearly identify samples and tests that are out-of-specification (OOS) and out-of-trend (OOT) as unique incidents.
|
21 CFR Part 606.100 (c)
42 CFR Part 493.1282
ASTM E1578-18 E-9-3
EPA QA/G-5 2.2.10
WHO Technical Report Series, #986, Annex 2, 17.12
|
16.5 The system should trigger an alert or notification when an OOS/OOT status is found, prompting a documented investigation to identify the root cause.
|
21 CFR Part 225.58 (d)
21 CFR Part 225.158
21 CFR Part 606.100 (c)
21 CFR Part 820.100
42 CFR Part 493.1282
ASTM E1578-18 E-9-4
E.U. Commission Directive 2003/94/EC Article 13
FDA Hazard Analysis Critical Control Point Principle 5
New York Department of Health ELAP Microbiology Protocol
NIST 800-53, Rev. 4, IR-5
WHO Technical Report Series, #986, Annex 2, 2.1 (f, j)
WHO Technical Report Series, #986, Annex 2, 5.0
|
16.6 The system shall allow for the documentation of and corrective and preventive action towards all types of nonconformance.
|
21 CFR Part 225.58 (d)
21 CFR Part 225.158
42 CFR Part 493.1282
42 CFR Part 493.1289
ASTM E1578-18 E-9-5
CJIS Security Policy 5.3.4
CJIS Security Policy Appendix G.7
E.U. Commission Directive 2003/94/EC Article 13
FDA Hazard Analysis Critical Control Point Principle 5
New York Department of Health ELAP Microbiology Protocol
NIST 800-53, Rev. 4, AU-6(1)
NIST 800-53, Rev. 4, IR-4(1) and IR-5
NIST 800-53, Rev. 4, SI-2 and SI-4
WHO Technical Report Series, #986, Annex 2, 2.1 (f, j)
WHO Technical Report Series, #986, Annex 2, 5.0
|
16.7 The system should track and record incidents and associated corrective actions, allowing authorized personnel to document the effectiveness of the actions, identify insufficient resolutions, and curb repeat occurrences.
|
ASTM E1578-18 E-9-6
|
16.8 The system should provide a means for configurable workflows to manage OOS and OOT incidents according to an organization’s standard operating procedures.
|
|